Is the Watson appeal holding back the OB from being updated with Vascepa exclusivlty? No, Judge Moss vacated FDA's prior decision of NME and ordered FDA to fix their mess.
FDA is not worried about tarnishing their image here - they do not want their power reduced, or an AMRN specific ruling being applied to a broader spectrum of companies - losing an appeal establishes further precedent.
Market Data 
Markets 
AI
